{
    "eid": "2-s2.0-85118876411",
    "title": "Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial",
    "cover-date": "2021-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Gastroenterology",
            "@code": "2715",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Rui Hua Xu",
        "Yanqiao Zhang",
        "Hongming Pan",
        "Jifeng Feng",
        "Tao Zhang",
        "Tianshu Liu",
        "Yanru Qin",
        "Shukui Qin",
        "Xianli Yin",
        "Baorui Liu",
        "Yi Ba",
        "Nong Yang",
        "Pei Jye Voon",
        "Suebpong Tanasanvimon",
        "Chan Zhou",
        "Wan Li Zhang",
        "Lin Shen"
    ],
    "citedby-count": 29,
    "ref-count": 30,
    "ref-list": [
        "GLOBOCAN 2020. Cancer fact sheets. Stomach",
        "The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021",
        "GLOBOCAN 2020. Population fact sheets. China",
        "Surveillance, Epidemiology, and End Results Program Cancer Stat Facts: Stomach Cancer. SEER 18 2011\u20132017, All Races, Both Sexes by SEER Summary Stage 2000",
        "Gastric cancer. Version 3",
        "A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01)",
        "Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer",
        "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial",
        "Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity",
        "Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity",
        "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial",
        "Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan",
        "The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology",
        "EuroQol\u2014a new facility for the measurement of health-related quality of life",
        "Chinese time trade-off values for EQ-5D health states",
        "Combination versus single-agent as palliative chemotherapy for gastric cancer",
        "Prognostic factor analysis of overall survival in gastric cancer from two phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data",
        "Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma",
        "Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction",
        "Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study",
        "Subgroup analysis of east Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer",
        "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study",
        "Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer",
        "Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial",
        "Overall survival as the outcome for randomized clinical trials with effective subsequent therapies",
        "Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: a meta-analysis of randomized controlled trials",
        "Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer",
        "A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study)",
        "Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial",
        "Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel"
    ],
    "affiliation": [
        {
            "affiliation-city": "Hangzhou",
            "@id": "60118427",
            "affilname": "Sir Run Run Shaw Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60118427",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Zhengzhou",
            "@id": "60102075",
            "affilname": "First Affiliated Hospital of Zhengzhou University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60102075",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Kuching",
            "@id": "60090650",
            "affilname": "Hospital Umum Sarawak",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60090650",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60082502",
            "affilname": "Sun Yat-Sen University Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082502",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "60073655",
            "affilname": "Zhongshan Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073655",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Nanjing",
            "@id": "60073601",
            "affilname": "Jiangsu Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073601",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Nanjing",
            "@id": "60033100",
            "affilname": "Nanjing University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033100",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Indianapolis",
            "@id": "60025685",
            "affilname": "Eli Lilly and Company",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025685",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Harbin",
            "@id": "60021615",
            "affilname": "Harbin Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021615",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Tianjin",
            "@id": "60017260",
            "affilname": "Tianjin Medical University Cancer Institute &amp; Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017260",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Changsha",
            "@id": "60017060",
            "affilname": "Central South University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017060",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Beijing",
            "@id": "60008510",
            "affilname": "Beijing Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008510",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Nanjing",
            "@id": "60005189",
            "affilname": "Nanjing University of Traditional Chinese Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005189",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Wuhan",
            "@id": "60001193",
            "affilname": "Tongji Medical College",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60001193",
            "affiliation-country": "China"
        }
    ],
    "funding": [
        "Eli Lilly and Company"
    ]
}